Raymond James Financial Services Advisors Inc. lowered its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 7.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,060 shares of the medical research company’s stock after selling 686 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Edwards Lifesciences were worth $1,021,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. ING Groep NV boosted its position in Edwards Lifesciences by 41.2% during the 3rd quarter. ING Groep NV now owns 22,905 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 6,684 shares during the period. ACG Wealth purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $252,000. JPMorgan Chase & Co. boosted its position in Edwards Lifesciences by 6.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 564,397 shares of the medical research company’s stock valued at $61,446,000 after buying an additional 33,347 shares during the period. D.A. Davidson & CO. boosted its position in Edwards Lifesciences by 8.2% during the 4th quarter. D.A. Davidson & CO. now owns 24,397 shares of the medical research company’s stock valued at $2,750,000 after buying an additional 1,842 shares during the period. Finally, Highbridge Capital Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $14,074,000. 81.31% of the stock is owned by institutional investors and hedge funds.
EW has been the subject of several analyst reports. JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Barclays upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. Cowen set a $135.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Sunday, December 10th. Canaccord Genuity restated a “buy” rating and issued a $174.00 price objective (up from $140.00) on shares of Edwards Lifesciences in a report on Friday, February 2nd. Finally, Evercore ISI assumed coverage on shares of Edwards Lifesciences in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Edwards Lifesciences presently has a consensus rating of “Buy” and an average target price of $141.15.
Edwards Lifesciences Corp (NYSE:EW) opened at $139.32 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41. The stock has a market cap of $29,260.54, a PE ratio of 36.66, a P/E/G ratio of 2.06 and a beta of 0.56. Edwards Lifesciences Corp has a 12 month low of $91.30 and a 12 month high of $140.07.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The company had revenue of $888.50 million during the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. Edwards Lifesciences’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period last year, the business earned $0.75 EPS. analysts anticipate that Edwards Lifesciences Corp will post 4.49 earnings per share for the current year.
Edwards Lifesciences announced that its board has authorized a share repurchase plan on Thursday, December 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.
In related news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $114.58, for a total value of $2,172,436.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the completion of the transaction, the vice president now owns 24,908 shares of the company’s stock, valued at $3,169,293.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 184,563 shares of company stock valued at $22,358,569. 2.13% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/11/raymond-james-financial-services-advisors-inc-has-1-02-million-holdings-in-edwards-lifesciences-corp-ew.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.